Cannabinoids and GI Disorders: Endogenous and Exogenous

被引:0
|
作者
Zachary Wilmer Reichenbach
Ron Schey
机构
[1] Temple University,Center for Substance Abuse Research (CSAR), Lewis Katz School of Medicine
[2] Temple University,Section of Gastroenterology, Department of Medicine, Lewis Katz School of Medicine
关键词
Cannabinoids; CB1 receptor; CB2 receptor; GPR55; Irritable bowel syndrome (IBS); GI motility; Visceral hypersensitivity;
D O I
10.1007/s11938-016-0111-1
中图分类号
学科分类号
摘要
Despite the political and social controversy affiliated with it, the medical community must come to the realization that cannabinoids exist as a ubiquitous signaling system in many organ systems. Our understanding of cannabinoids and how they relate not only to homeostasis but also in disease states must be furthered through research, both clinically and in the laboratory. The identification of the cannabinoid receptors in the early 1990s have provided us with the perfect target of translational research. Already, much has been done with cannabinoids and the nervous system. Here, we explore the implications it has for the gastrointestinal tract. Most therapeutics currently on the market presently target only one aspect of the cannabinoid system. Our main purpose here is to highlight areas of research and potential avenues of discovery that the cannabinoid system has yet to reveal.
引用
收藏
页码:461 / 477
页数:16
相关论文
共 50 条
  • [1] Modulation of synaptic transmission by exogenous and endogenous cannabinoids
    Szabo, B.
    Wallmichrath, I.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 9 - 9
  • [2] Exogenous and Endogenous Cannabinoids Suppress Inhibitory Neurotransmission in the Human Neocortex
    Flora E Kovacs
    Tim Knop
    Michal J Urbanski
    Ilka Freiman
    Thomas M Freiman
    Thomas J Feuerstein
    Josef Zentner
    Bela Szabo
    Neuropsychopharmacology, 2012, 37 : 1104 - 1114
  • [3] Exogenous and Endogenous Cannabinoids Suppress Inhibitory Neurotransmission in the Human Neocortex
    Kovacs, Flora E.
    Knop, Tim
    Urbanski, Michal J.
    Freiman, Ilka
    Freiman, Thomas M.
    Feuerstein, Thomas J.
    Zentner, Josef
    Szabo, Bela
    NEUROPSYCHOPHARMACOLOGY, 2012, 37 (05) : 1104 - 1114
  • [4] Activation of G-proteins in brain by endogenous and exogenous cannabinoids
    Steven R. Childers
    The AAPS Journal, 8
  • [5] Endogenous and exogenous cannabinoids in the development and course of schizophrenia: What is the evidence?
    D'Souza, D
    Murray, R
    Weiser, M
    Green, A
    Leweke, M
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 220 - 220
  • [6] Activation of G-proteins in brain by endogenous and exogenous cannabinoids
    Childers, SR
    AAPS JOURNAL, 2006, 8 (01): : E112 - E117
  • [7] ANXIETY DISORDERS - EXOGENOUS VS ENDOGENOUS
    FONTAINE, R
    MOREIRA, F
    UNION MEDICALE DU CANADA, 1986, 115 (06): : 402 - 407
  • [8] Exogenous and endogenous cannabinoids control synaptic transmission in mice nucleus accumbens
    Robbe, D
    Alonso, G
    Manzoni, OJ
    GLUTAMATE AND DISORDERS OF COGNITION AND MOTIVATION, 2003, 1003 : 212 - 225
  • [9] Modulating endogenous cannabinoids to treat pain and affective disorders
    Piomelli, Daniele
    NEUROPSYCHOPHARMACOLOGY, 2008, 33 (01) : 207 - 207
  • [10] Exogenous Δ9-tetrahydrocannabinol influences circulating endogenous cannabinoids in human
    Walter, C.
    Ferreiros, N.
    Geisslinger, G.
    Tegeder, I
    Loetsch, J.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S88 - S88